STUDY OBJECTIVE: The aim of this study was to compare 2 groups of patients with severe obstructive sleep apnea (OSA) who were taking medication for cardiovascular disease: those who were compliant with nasal continuous positive airway pressure (CPAP) treatment and those who refused treatment or were noncompliant with CPAP treament. METHODS: In a cohort of 2158 patients with severe OSA (apnea-hypopnea index >30) a 2-year prospective longitudinal assessment of adherence and persistence with 3 medication categories (antihypertensives, statins, and antiplatelets) was carried out using the administrative database of the National Health Service. Medication adherence was evaluated by calculating the medication possession ratio (%MPR = days supplylactual days to refill x 100) for each drug. Medication persistency was defined as the proportion of subjects having filled a prescription in the last 30 days of the 2-year period. CPAP use was assessed at every follow-up visit after the treatment was prescribed. Medication adherence was compared between patients who had adequate CPAP adherence (> 4 h/day) and those who declined CPAP therapy or had discontinued CPAP due to an average use of less than 4 hours per day. RESULTS: The average 2-year MPR for antihypertensives, statins, and antiplatelets was not different among patients who used CPAP (88%, 81%, 95%) or did not use CPAP (86%, 77%, 93%). Female sex and increased number of comorbidities were predictors of good medication adherence (MPR > 80%). The rates of persistence for the 3 studied medications after the 2-year observation period were not different between the 2 groups (patients with or without CPAP). CONCLUSIONS: Medication adherence and persistence during a 2-year period for 3 well-known protective cardiovascular medications were not different in patients with severe OSA, whether or not they were treated with CPAP.
STUDY OBJECTIVE: The aim of this study was to compare 2 groups of patients with severe obstructive sleep apnea (OSA) who were taking medication for cardiovascular disease: those who were compliant with nasal continuous positive airway pressure (CPAP) treatment and those who refused treatment or were noncompliant with CPAP treament. METHODS: In a cohort of 2158 patients with severe OSA (apnea-hypopnea index >30) a 2-year prospective longitudinal assessment of adherence and persistence with 3 medication categories (antihypertensives, statins, and antiplatelets) was carried out using the administrative database of the National Health Service. Medication adherence was evaluated by calculating the medication possession ratio (%MPR = days supplylactual days to refill x 100) for each drug. Medication persistency was defined as the proportion of subjects having filled a prescription in the last 30 days of the 2-year period. CPAP use was assessed at every follow-up visit after the treatment was prescribed. Medication adherence was compared between patients who had adequate CPAP adherence (> 4 h/day) and those who declined CPAP therapy or had discontinued CPAP due to an average use of less than 4 hours per day. RESULTS: The average 2-year MPR for antihypertensives, statins, and antiplatelets was not different among patients who used CPAP (88%, 81%, 95%) or did not use CPAP (86%, 77%, 93%). Female sex and increased number of comorbidities were predictors of good medication adherence (MPR > 80%). The rates of persistence for the 3 studied medications after the 2-year observation period were not different between the 2 groups (patients with or without CPAP). CONCLUSIONS: Medication adherence and persistence during a 2-year period for 3 well-known protective cardiovascular medications were not different in patients with severe OSA, whether or not they were treated with CPAP.
Authors: Jeffrey J Ellis; Steven R Erickson; James G Stevenson; Steven J Bernstein; Renee A Stiles; A Mark Fendrick Journal: J Gen Intern Med Date: 2004-06 Impact factor: 5.128
Authors: Karen Dahri; Stephen J Shalansky; Linda Jang; Leon Jung; Andrew P Ignaszewski; Catherine Clark Journal: Ann Pharmacother Date: 2008-02-26 Impact factor: 3.154
Authors: Meghna P Mansukhani; Bhanu Prakas Kolla; James M Naessens; Peter C Gay; Timothy I Morgenthaler Journal: J Clin Sleep Med Date: 2019-01-15 Impact factor: 4.062
Authors: Paula Casas; Francisco J Ascaso; Eugenio Vicente; Gloria Tejero-Garcés; María I Adiego; José A Cristóbal Journal: Graefes Arch Clin Exp Ophthalmol Date: 2013-02-03 Impact factor: 3.117
Authors: José M Marin; Alvar Agusti; Isabel Villar; Marta Forner; David Nieto; Santiago J Carrizo; Ferran Barbé; Eugenio Vicente; Ying Wei; F Javier Nieto; Sanja Jelic Journal: JAMA Date: 2012-05-23 Impact factor: 56.272
Authors: Erna S Arnardottir; Diane C Lim; Brendan T Keenan; Greg Maislin; Bryndis Benediktsdottir; Sigurdur Juliusson; Allan I Pack; Thorarinn Gislason Journal: J Sleep Res Date: 2014-10-31 Impact factor: 3.981
Authors: Alec B Platt; Samuel T Kuna; Samuel H Field; Zhen Chen; Rajesh Gupta; Dominic F Roche; Jason D Christie; David A Asch Journal: Chest Date: 2009-10-09 Impact factor: 9.410
Authors: Marcus Povitz; Willis H Tsai; Sachin R Pendharkar; Patrick J Hanly; Matthew T James Journal: J Clin Sleep Med Date: 2016-04-15 Impact factor: 4.062